On November 25, 2019 WuXi Biologics ("WuXi Bio") (2269.HK), a world-leading open access technology platform for biologics that provides complete solutions for the discovery, development and manufacture of biological compounds , has reported that its subsidiary WuXi Vaccines, a human factor vaccine development and production company (CDMO), is investing $ 240 million in a new vaccines manufacturing facility in Ireland, following a LOI of 20 years, WuXi Vaccines Signed at the beginning of the year (Press release, WuXi Biologics, NOV 25, 2019, View Source [SID1234551635]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
WuXi Vaccines to Build a $ 240 Million Manufacturing Facility in Ireland
WuXi Vaccines to Build a $ 240 Million Manufacturing Facility in IrelandLatest Image of WuXi Biologics Factory of the Future in Ireland
The Memorandum of Understanding covers a new, dedicated manufacturing facility, including production of active pharmaceutical ingredients (MFG15), manufacturing of pharmaceutical products (DP5) and quality control (QC) laboratories. A vaccine product is being produced there for a large international pharmaceutical company that is to be marketed worldwide. The new vaccine production site, which is scheduled to be approved, will be built within the WuXi Biologics campus, adjacent to the "Factory of the Future." The biologic drug manufacturing facility is scheduled to begin commercial production in 2021.
Heather Humphreys TD , Irish Minister for the Economy, Enterprise and Innovation said: "I am delighted that WuXi Vaccines is creating 200 highly skilled jobs. These are added to the 400 jobs that WuXi Biologics announced last year for Dundalk. Today’s news is further proof that the border region is an attractive investment location. "
Eileen Sharpe , Head of Growth, Europe and New Business Units at the Irish Industrial Development Authority (IDA) commented, "A second major investment by WuXi Biologics at its Dundalk site is great news. As the first contract manufacturing operation in Ireland, this second planned project will significantly strengthen our life science ecosystem and provide important impetus for Ireland as a production location. "
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines, commented, "We look forward to our first production facility in Ireland, where a vaccine for a major international pharmaceutical company is being manufactured. Complex processes, extensive analytical testing and strict regulatory requirements make vaccine production difficult. Process and quality control are extremely important for product quality. This new project covers the exclusive production of a vaccine for a major international pharmaceutical company to be marketed worldwide. It is one of the first of its kind in the industry and further demonstrates the technical expertise, world-class quality and commercial manufacturing expertise that WuXi Biologics will bring to Dundalk. WuXi Biologics and WuXi Vaccines are eager to